7 November 2026

To
The Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Symbol: COHANCE

To
The Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Mumbai – 400 001

Code – 543064

Dear Sir/Madam,

Sub: Update on USFDA Inspection for Company's Pashamylaram Manufacturing Facility

Further to our earlier communication dated 5 August 2026 regarding the inspection by the United States Food and Drug Administration (USFDA) at the Company's manufacturing facility located at Pashamylaram, Hyderabad (FEI No. 1000623515), we wish to update that USFDA has issued the Establishment Inspection Report (EIR) in respect of the aforesaid facility and has classified the inspection outcome as Voluntary Action Indicated (VAI).

With the receipt of the EIR, the said inspection stands concluded.

Kindly take the above information on record.

Thank you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)
Sisira Kumar Mishra
Digitally signed by Sisira Kumar Mishra
Date: 2026.11.07 11:07:41 +05'30'
Sisir K Mishra
Company Secretary and Compliance Officer